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SUMMARY  
Recent advances in DNA sequencing technology have led to an unprecedented period of 
disease-gene discovery offering many new opportunities for genetic testing in the clinical 
setting. Endocrinology has seen a rapid expansion in the taxonomy of monogenic disorders, 
which can be detected by an expanding portfolio of genetic tests in both diagnostic and 
predictive settings. Successful testing relies on many factors including the ability to identify 
those at increased risk of genetic disease in the busy clinic as well as a working knowledge 
of the various testing platforms and their limitations. The clinical utility of a given test is 
dependent upon many factors, which include the reliability of the genetic testing platform, the 
accuracy of the test result interpretation and knowledge of disease penetrance and 
expression. The increasing adoption of ‘high-content’ genetic testing based on next-
generation sequencing (NGS) to diagnose hereditary endocrine disorders brings a number 
of challenges including the potential for uncertain test results and/or genetic findings 
unrelated to the indication for testing. Therefore, it is increasingly important that the clinician 
is aware of the current evolution in genetic testing, and understands the different settings in 
which it may be employed. This review provides an overview of the genetic testing workflow, 
focusing on each of the major components required for successful testing in adult and 
paediatric endocrine settings. In addition, the challenges of variant interpretation are 
highlighted, as are issues related to informed consent, prenatal diagnosis and predictive 
testing. Finally, the future directions of genetic testing relevant to endocrinology are 
discussed. 
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INTRODUCTION  
Establishing a genetic diagnosis may have many potential benefits for the patient and wider 
family. Until recently, genetic testing in the endocrine clinic was typically reserved for the 
diagnosis of a limited number of hereditary monogenic syndromes (e.g. Multiple Endocrine 
Neoplasia Type 1 (MEN1) or Type 2 (MEN2)) or disorders associated with an abnormal 
complement of sex chromosomes (e.g. Turner syndrome, Klinefelter syndrome). However, 
recent advances in DNA sequencing technologies (i.e. ‘next-generation sequencing’ (NGS)) 
have resulted in an intense period of disease-gene discovery, and a greater insight into the 
molecular-genetic basis of many endocrine disorders.1,2 These advances now offer many 
new opportunities for genetic testing in the clinical setting and the potential for improved 
health outcomes. At the same time, the increased use of genetic testing brings many 
challenges, not least those associated with accurate test interpretation and deciphering the 
impact of genetic variation on human health.3-5 Therefore, prior to the widespread adoption 
of new testing strategies it is important to consider both the potential utility and validity of any 
given test, as well as evaluating any harm that may arise.  For example, factors that 
influence the clinical utility and validity of a genetic test include: the genetic heterogeneity of 
the disorder; the reliability of the test result (i.e. accuracy of variant interpretation); and 
knowledge regarding disease penetrance and expressivity. In contrast, potential harm may 
arise from variant misclassification (e.g. benign variants reported as pathogenic), uncertain 
test results or the identification of incidental findings (i.e. genetic changes unrelated to the 
indication for testing), as well as psychological impacts from testing. It is increasingly 
important that the clinician has an awareness of these considerations when deciding 
whether genetic testing is indicated, as injudicious use may result in clinical uncertainty 
and/or unfavourable outcomes. This review provides an overview of each component of the 
genetic testing workflow, focusing on how such testing may be integrated into the overall 
clinical evaluation of the patient. In addition, it highlights several of the current challenges, 
before discussing possible future directions of genetic testing relevant to the endocrine field.  
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GENETIC BASIS OF ENDOCRINE DISEASE 
The successful application of genetic testing in the clinical setting relies upon an accurate 
understanding of the genetic architecture of the disease or phenotype in question6. In the 
broadest sense, genetic architecture refers to the landscape of heritable genetic variation 
that contributes to a given phenotype, and includes the number of variants influencing a 
phenotype their effect size and frequency in the population, as well their interaction with 
each other and the environment.6 Although the contribution of genetic variation to many 
phenotypes frequently represents a continuum, in the clinical context, genetic architecture is 
frequently divided into single-gene monogenic disorders and oligogenic/polygenic complex 
traits. Currently, the majority of genetic testing employed in the endocrine clinic focuses on 
the detection of monogenic ‘Mendelian’ disorders and these are the predominant focus of 
this review. A smaller number of endocrine disorders resulting from large structural genetic 
changes (i.e. chromosomal abnormalities) may also be amenable to genetic testing and are 
briefly discussed.  
 
Monogenic Endocrine Disease 
Monogenic endocrine disorders most frequently result from germline mutations affecting the 
coding sequence of the responsible gene. The successful recognition and diagnosis of these 
disorders relies on knowledge of: the mode of inheritance; the types of genetic abnormality 
responsible for disease; the disease penetrance and clinical expressivity; and the degree of 
genetic heterogeneity.  
 
Mode of inheritance: Monogenic disorders may be inherited in one of six patterns (Table 
1); autosomal dominant (e.g. MEN1 and MEN2 due to mutations in the MEN1 and RET 
genes, respectively); autosomal recessive (e.g. 21-hydroxylase deficiency due to mutation in 
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the CYP21A2 gene); X-linked dominant (e.g. X-linked hypophosphataemic rickets due to 
mutation in the PHEX gene), X-linked recessive (e.g. Kallman Syndrome due to 
ANOS1/KAL1 mutation); Y-linked (e.g. azoospermia and oligospermia due to deletions of 
part of the Y-chromosome (e.g. USP9Y gene)); and non-Mendelian mitochondrial 
inheritance (e.g. hypogonadotrophic hypogonadism and hypoparathyroidism associated with 
Kearns-Sayre syndrome due to mitochondrial DNA (mtDNA) deletion)).7 In addition, germline 
mosaicism, in which a post-zygotic mutation occurs in the germ cells of a parent, may result 
in an apparent autosomal recessive pattern of inheritance, with multiple affected offspring of 
unaffected parents (e.g. observed for Carney complex and osteogenesis imperfecta type 
II).8,9 Parent-of-origin effects may also be observed due to genomic imprinting. The clinical 
effects of pathogenic GNAS, SDHD and SDHAF2 variants are determined by their parental 
origin. Maternally-inherited inactivating GNAS mutations give rise to Albright hereditary 
osteodystrophy (AHO) with resistance to multiple hormones (i.e. pseudohypoparathyroidism 
type 1a), whilst the equivalent paternally-inherited mutation gives rise to AHO without 
accompanying endocrine problems (pseudopseudohypoparathyroidism).10 The development 
of phaeochromocytoma/paraganglioma (PPGL) in patients harbouring SDHD or SDHAF2 
mutations is usually limited to those with paternally-inherited variants.11-14 Monogenic 
endocrine syndromes may also occur in the absence of an inherited defect due to de novo 
mutations (i.e. mutations arising during parental gametogenesis, or post-zygotically in the 
developing embryo). For example, the majority of cases of MEN2B and X-linked 
Acrogigantism (XLAG) result from such de novo genetic events (Table 1).15-17  
 
Genetic abnormalities leading to monogenic disease: The most common genetic 
abnormalities associated with monogenic endocrine disorders are either single nucleotide 
variants (SNVs) (substitution of one nucleotide by another) or small insertions or deletions 
(indels) affecting the coding-region or splice sites of the associated gene. Disease-
associated SNVs typically result in missense amino acid substitutions, nonsense mutations, 
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or defects in splicing, whilst in-frame indels typically disrupt protein function through gains or 
losses of one or more amino acids, amino acid substitutions, generation of stop codons (i.e. 
nonsense mutations) or defects in splicing (for descriptions see Glossary of Terms). SNVs 
and out-of-frame indels (frameshift changes) that predict a premature truncation of amino 
acid sequence frequently result in a loss-of-function (LOF) of the gene. In addition to SNVs 
and indels, monogenic disorders may also result from larger structural genetic defects (e.g. 
copy number variations (CNVs)) including partial or whole gene deletions (e.g. VHL, MEN1, 
Carney Complex) as well as gene duplications (e.g. XLAG). 
Disease penetrance and expressivity: Penetrance refers to the likelihood that an 
individual carrying a disease-causing variant will manifest the disorder (Figure 1).18 Many 
monogenic disorders are highly penetrant, such that close to 100% of variant carriers 
manifest disease (e.g. MEN1). In contrast, several display reduced penetrance; for example, 
mutations in AIP are reported to be associated with a ~20-25% risk of pituitary tumour 
development;19-21 whilst the risk of PPGL in non-proband SDHB and paternally-inherited 
SDHD mutation carriers is reported to be ~22% and ~44% at 60 years of age, 
respectively.11,12 Furthermore, penetrance may vary substantially between alleles in the 
same gene.22 For example, population-based studies indicate that the p.Val804Met RET 
variant confers a much lower lifetime risk of medullary thyroid cancer (MTC) than other 
MEN2A-associated RET mutations.23,24 For variants with reduced penetrance, the additional 
genetic and/or environmental factors contributing to disease expression remain to be 
defined. Disease expressivity refers to the range of disease phenotypes observed between 
individuals harbouring the same variant. For some monogenic disorders, individuals carrying 
the same variant, even within the same kindred, may manifest markedly different 
phenotypes (e.g. Neurofibromatosis Type 1 (NF1), MEN1).25,26 In contrast, some disorders 
display a strong genotype-phenotype correlation. For example, in MEN2, clinical 
expression and disease severity are predicted by the specific RET mutation,27 whilst 
in Carney complex, large-scale deletions of the PRKAR1A locus typically result in 
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more severe phenotypes than those associated with PRKAR1A SNVs or indels, 
presumably due to the loss of additional genes in adjacent genomic regions.28,29  
 
Genetic heterogeneity. Genetic heterogeneity describes the situation in which similar clinical 
phenotypes may result from different genetic abnormalities. For example, germline 
mutations in >15 different genes have been reported in patients with hereditary PPGL,30 
whilst genetic defects in >30 genes have been implicated in autosomal forms of 
hypogonadotrophic hypogonadism.31,32 In some instances, different variants in the same 
gene may give rise to different clinical phenotypes (e.g. loss- and gain-of-function RET 
mutations associated with Hirschsprung disease, and MEN2, respectively), whilst in other 
situations the severity of disease is determined by whether there is a dominant or recessive 
pattern of inheritance (e.g. severe perinatal and infantile forms of hypophosphatasia result 
from autosomal recessive TNSALP mutations, whilst later-onset forms are typically inherited 
in an autosomal dominant manner).33 
 
Chromosomal Disorders 
Large-scale abnormalities affecting all or part of one or more chromosomes may account for 
several endocrine genetic disorders. These include conditions associated with an abnormal 
number of sex chromosomes (i.e. aneuploidy) such as Klinefelter (47, XXY) and Turner 
(45,X0) syndromes. Alternatively, there may be gains or losses of chromosomal material 
(e.g. 22q11.2 deletion syndrome, or Prader-Willi syndrome (Table 1), as well as 
translocations and inversions. Typically these genetic abnormalities are not inherited, 
instead arising from errors in cell division during gametogenesis or early embryonic 
development, although autosomal patterns of inheritance may occur if fertility is preserved 
(e.g. ~15% of cases of 22q11 deletion syndrome are inherited from an affected parent). The 
phenotype is associated with the gains or losses of genetic material and there be overlap 
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with monogenic disorders (e.g. 17q24.2-q24.3 deletions which include the PRKAR1A gene 
demonstrate features of Carney complex).29 Several chromosomal disorders may be 
associated with mosaicism (e.g. Turner and Klinefelter syndrome), in which the error 
in mitosis arises post-fertilization (i.e. during early embryonic development), and 
patients frequently manifest milder phenotypes.8  
 
 APPLICATION OF GENETIC TESTING 
 
Potential Value of genetic testing 
The decision to undertake genetic testing should be driven by the likelihood of it contributing 
to improved health outcomes in the patient or wider family. In some instances the benefits 
may be clear (e.g. guiding specific treatment or intervention), whilst in other situations, the 
benefits (and conversely, the potential harms) may be harder to quantify. The potential value 
of a given test is dependent on the clinical utility and validity in relation to the specific clinical 
context.34  
 
Clinical utility:  Establishing the clinical utility of a test can be challenging, as this may not 
only concern the patient, but also the wider family. For the patient, a genetic diagnosis may 
have important diagnostic, prognostic and therapeutic implications. For example, a diagnosis 
of MEN1 in a patient may lead to the early detection of otherwise asymptomatic tumours 
through the implementation of surveillance screening programmes.26 Genetic testing may 
guide patient follow up; for example, patients with PPGL due to SDHB mutations are at a 
higher risk of metastatic or recurrent disease.11,35 In some instances a genetic diagnosis may 
guide therapy; for example, children with infantile hypophosphatasia (i.e. due to bi-allelic 
TNSALP mutations) may benefit from enzyme replacement therapy with alfotase-
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alpha.33,36,37 Genetic testing may also resolve diagnostic uncertainty, thereby avoiding 
additional downstream investigations and/or treatment,38,39 whilst negative genetic testing 
may alleviate anxiety and/or uncertainty for the patient. Often, establishing a genetic 
diagnosis in a patient has benefit to family members by enabling predictive testing of ‘at-risk’ 
individuals (e.g. first-degree relatives). In this setting, family members identified to carry the 
mutation can receive appropriate clinical care (e.g. surveillance and/or treatment), whilst 
relatives not harbouring the mutation can be reassured. For example, the detection of 
MEN2-associated RET mutations in patients with MTC, may facilitate ‘prophylactic’ 
thyroidectomy in ‘at-risk’ children (i.e. individuals harbouring high-risk RET mutations) prior 
to the onset of advanced disease.27 Establishing a genetic diagnosis may also provide 
valuable information in the pre-pregnancy or antenatal settings, facilitating genetic 
counselling, pre-conception and/or pre-natal genetic testing.40 Finally, in some instances the 
clinical value of genetic testing may only emerge over time through clinical research 
initiatives. For example, the collection and sharing of detailed phenotypic and genetic data 
from patients with ultra-rare disorders may facilitate novel disease gene discovery.4,39 Any 
potential clinical benefits of testing must be counterbalanced against any harm that might 
arise, which could include; negative psychological impacts of being labelled with a genetic 
diagnosis; guilt over transmission to family members; and the potential for stigmatisation 
and/or negative discrimination.  
 
Clinical Validity: For optimal clinical application, a genetic test should have high clinical 
sensitivity, maximal specificity and be cost effective. Clinical validity defines the accuracy 
with which the test predicts a particular disease or phenotype and is determined by several 
factors including: the certainty with which a given genetic variant is associated with the 
disorder; the likelihood that a pathogenic variant carrier will develop disease (i.e. 
penetrance); the degree of genetic heterogeneity; and the extent of clinical expressivity. It is 
also important to consider the clinical setting of the test. For example, uncertainty over 
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variant pathogenicity and/or penetrance will substantially reduce the validity of testing in the 
predictive setting.  
 
IDENTIFYING PATIENTS WITH GENETIC DISEASE IN THE CLINICAL SETTING 
 
Genetic testing is typically requested following the identification of a particular clinical 
phenotype and/or establishing a relevant family history.  Several features in the clinical 
presentation may alert the clinician to the possibility of a genetic disorder (Figure 2), and 
include: the identification of specific clinical features either individually or in combination (e.g. 
marfanoid habitus with multiple mucosal neuromas in MEN2B, café-au-lait patches and 
axillary freckling in Neurofibromatosis Type 1); an early age of disease-onset (e.g. ~50% of 
young children and adolescents with primary hyperparathyroidism are reported to have an 
underlying monogenic disorder);41 ‘severe’ clinical features (e.g. parathyroid carcinoma in 
the Hyperparathyroidism-Jaw Tumour Syndrome); and tumour multiplicity, including 
combinations of both endocrine and non-endocrine tumours (Table 1).  
 
The patient’s family history is paramount in establishing a genetic diagnosis (and in 
determining the likely mode of inheritance). However, often limited information is available 
due to: medical histories not being shared between family members; geographical or social 
separation of the kindred; relatives dying prematurely of causes unrelated to the disorder; 
incomplete or variable disease penetrance; small kindred size with insufficient family 
members to establish clear pedigrees; or instances of non-paternity. Knowledge of the 
geographical origin of the kindred may also be important, and indicate the presence of a 
known founder mutation (e.g. acromegaly/gigantism due to the Arg304Ter AIP variant in 
Ireland,42 MEN2A due to Cys611Tyr RET mutation in Denmark).43 A relevant family history 
will be absent in instances of de novo mutation (e.g. the majority of patients with MEN2B, 
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female cases with XLAG), disorders associated with somatic mosaicism (e.g. McCune-
Albright syndrome, sporadic male cases with XLAG), and is often absent for autosomal 
recessive disorders and disorders with reduced disease penetrance.  
 
The recognition and diagnosis of genetic disease in the paediatric setting requires specialist 
expertise. Several monogenic endocrine disorders present in the neonatal period or early 
childhood (e.g. disorders/differences of sexual development (DSDs), congenital 
hyperinsulinism due to ABCC8 or KNJ11C mutations, neonatal severe hyperparathyroidism 
due to homozygous CASR mutations, or diabetic phenotypes due to mutations in genes 
involved in pancreatic development or β-cell function).44-48 Furthermore, endocrine 
manifestations may be a component of complex paediatric phenotypes due to structural 
genetic abnormalities.49 Again, establishing relevant family history is essential. A history of 
parental consanguinity significantly increases the likelihood of autosomal recessive disease 
(e.g. congenital hypothyroidism/thyroid dysgenesis due to homozygous TSHR mutations).50 
Establishing a genetic diagnosis in infants and children may have several benefits including: 
establishing appropriate treatment (e.g. early thyroidectomy in patients with MEN2B); 
alerting the clinician to the possibility of co-existing and/or future health problems; and 
facilitating appropriate genetic counselling to parents with regard risks to future offspring.  
 
Predictive genetic testing in asymptomatic individuals: The testing of individuals at 
increased risk of genetic disease (e.g. first-degree relatives of patients harbouring 
pathogenic variants) is typically the remit of the clinical genetics team, requiring appropriate 
genetic counselling. The utility of predictive testing relies on accurate estimates of variant 
pathogenicity and penetrance as well as the evidence base supporting downstream clinical 
interventions based on screening results (e.g. surveillance imaging for hereditary tumour 
syndromes). Where the meaning of prior genetic testing results in the family is uncertain 
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(e.g. identification of a variant of uncertain significance (VUS)), predictive testing is not 
usually recommended, although support for pathogenicity may evolve if the variant is 
subsequently observed in additional family members who later develop the disease, or is 
reported in affected individuals from other kindreds. Where first-degree relatives already 
manifest clinical features suggestive of the disorder, genetic testing is still recommended as 
such individuals may represent phenocopies (i.e. appearing to have a trait or disease 
associated with a particular genotype, who do not carry that genotype).51 For example, a 
first-degree relative of a patient with a known MEN1 mutation, who has a pituitary adenoma, 
may not harbour the familial MEN1 mutation but instead have a sporadic pituitary tumour.51 
Predictive testing in the paediatric setting is usually only appropriate for disorders, which are 
likely to have a childhood-onset, and for young children will require authorization from a 
parent or guardian. Predictive testing in children for adult-onset conditions is not usually 
recommended and is typically deferred until an age where the individual can make their own 
decisions regarding testing.52 
 
Ethical Considerations and Informed Consent  
Obtaining informed consent is an essential component of the genetic testing workflow 
(Figure 2) and should be tailored to the individual and the test in question. Pre-test 
counselling should aim to address patient concerns and frequently covered issues include 
the implications of positive test results for family members and the risk of transmission to 
children. Whilst the majority of patients are willing to share information with family members, 
occasional conflicts may arise. Different viewpoints have been expressed regarding the 
obligation of affected individuals to share information with ‘at-risk’ first-degree relatives, 
although appropriate genetic counselling often resolves such issues. In the paediatric 
setting, conflicts may arise if parents are reluctant to give consent for diagnostic or predictive 
testing of their children, whilst the inclusion of parental DNA samples to improve diagnostic 
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yield (e.g. identification of de novo mutations through ‘trio’ testing), has the potential to 
reveal genetic findings relevant to the parents’ health (e.g. BRCA mutations). Specific policy 
statements on genetic testing of children have been published to cover some of the 
complexities that may arise.52 A further common concern of patients undergoing genetic 
testing is whether there will be implications for future employment or ability obtaining health-
related insurance.  Many countries have legislation in place to protect individuals from such 
discrimination (e.g. the Genetic Information Non-discrimination Act (GINA) in the United 
States). In the United Kingdom, a voluntary moratorium exists between the government and 
insurance industry, which aims to avoid such discrimination.  High-content genetic testing 
(i.e. gene-panel, whole exome sequencing (WES), whole genome sequencing (WGS)) 
raises many additional ethical issues including: whether samples should be analysed for the 
presence of ‘actionable’ variants in genes unrelated to the disease phenotype (i.e. 
incidental findings); how the large-data files generated can be stored safely whilst 
protecting patient privacy; and the extent to which genetic and phenotypic data should 
shared with the wider scientific community. 
 
GERMLINE GENETIC TESTING – SELECTING THE OPTIMAL TEST 
The selection of the most appropriate test is determined by a number of factors including the 
likely genetic abnormality present (e.g. SNV, indel or structural abnormality), the genetic 
heterogeneity of the disorder, the availability of samples from additional family members, 
and whether testing is being undertaken in the diagnostic or predictive setting.  In most 
instances, the detection of monogenic endocrine disorders genetic testing requires high-
resolution DNA sequencing, whilst the diagnosis of disorders associated with larger 
chromosomal abnormalities requires alternate methods.  
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Tests to detect Chromosomal Abnormalities 
Detection of aneuploidy and large chromosomal abnormalities: Conventional karyotyping 
detects abnormalities of chromosome number (e.g. aneuploidy) or structure (e.g. CNVs, 
inversions, translocations) with limited genomic resolution (e.g. 3-10Mb). In the endocrine 
clinic, karyotyping is frequently requested to detect Turner or Klinefelter syndrome, although 
is increasingly replaced with array comparative genomic hybridisation (aCGH), which has 
improved resolution (typically 100-400kb), and may also detect a proportion of those with 
mosaicism. aCGH detects the majority of structural abnormalities (with the potential 
exception of balanced translocations) and is commonly used as the first-line genetic 
investigation for the children with neurodevelopmental delay or congenital abnormalities,49 
and includes evaluation for the 22q11.2 deletion syndrome and Prader-Willi syndrome 
(Table 1). Additional methods to detect structural changes include: fluorescence in situ 
hybridization (FISH), which can be designed to identify abnormalities located to specific 
chromosomal regions (e.g. translocations); whole-genome SNP array and droplet digital 
PCR (ddPCR) to detect CNVs;53 and multiplex-ligation dependent probe amplification 
(MLPA), which is commonly used to detect partial or whole gene deletions associated with 
several monogenic disorders (e.g. MEN1, VHL) (Table 1).  
 
DNA sequencing 
High-resolution DNA sequencing is required for the diagnosis of the majority of monogenic 
disorders, although the content of available tests varies by several orders of magnitude 
(Figure 3)54. Whilst the sequencing of individual genes by Sanger-based methods has been 
the mainstay of genetic testing over the past decades, NGS-based methods are increasingly 
employed, providing a highly cost-effective and time-efficient method for genetic 
diagnosis.4,54 Determining the optimal strategy for DNA sequencing is dependent on the 
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clinical setting and in particular the degree of genetic heterogeneity associated with the 
specific phenotype or disorder (Figure 3). 
 
Low content genetic testing: single-variant, single-gene or pauci-gene testing: Where a 
disease phenotype is highly likely to be caused by a mutation in a single gene (i.e. disorders 
with low genetic heterogeneity), limiting the DNA sequence analysis to the relevant gene 
provides an effective strategy for diagnosis. Sanger sequencing is usually employed for such 
single-gene tests, in which the coding exons (and splice junctions) are amplified using the 
polymerase chain reaction (PCR) and sequenced with a high-fidelity DNA-polymerase 
(Figure 3). Although Sanger sequencing provides the “gold-standard’ for DNA sequencing, 
such an approach becomes inefficient if multiple genes require evaluation and in this setting 
NGS approaches offer many advantages (Figure 3). Sanger sequencing retains an 
important role in the context of predictive genetic testing, in which DNA sequence analysis is 
limited to confirming the presence or absence of a specific pathogenic variant (i.e. in first-
degree relatives of a known mutation carrier). Sanger sequencing is also often used to 
confirm the presence of likely pathogenic variants detected by clinical NGS methods.   
 
High Content Genetic Testing and NGS methods 
The fundamental advance of any of the NGS methods is the concept of ‘massive parallel 
sequencing’, which describes the simultaneous automated acquisition of DNA sequence of 
millions of short DNA fragments, which are subsequently assembled into meaningful data by 
aligning to a reference genome.4,54,55 The genomic content of the test is determined by the 
degree of enrichment of specific DNA regions prior to sequencing. Whilst highly cost-
effective for the acquisition of raw DNA sequence data, NGS platforms typically require 
bioinformatic support, and variant interpretation is often challenging (Figure 3).      
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Disease-targeted Gene Panels 
The current major application of NGS methods in the clinical setting involves the use of 
disease-targeted gene panels. This approach is suited to disorders associated with locus 
heterogeneity in which variants in one of many potential genes may be responsible for 
disease. In this method custom-designed oligonucleotide probes or primer-sets are designed 
to capture and amplify regions of interest (i.e. exonic regions of relevant genes), prior to 
sequencing with an appropriate NGS platform. Compared with more comprehensive NGS 
methods (e.g. WES/WGS), the bioinformatic/variant interpretation pipeline is usually more 
straightforward (Figure 3). Disease-targeted gene panels are increasingly employed in the 
endocrine setting and may be used to evaluate patients with a range phenotypes including: 
disorders of calcium homeostasis; endocrine tumours (e.g. PPGL); pituitary disorders (e.g. 
combined pituitary hormone deficiency (CPHD), isolated GnRH deficiency); 
monogenic/oligogenic forms of idiopathic hypogonadotrophic hypogonadism (IHH); 
DSDs; and monogenic neonatal and infancy-onset diabetes (Table 1).30,48,56 As the content 
of the genetic test increases the potential for identifying variants of uncertain significance 
(VUSs) increases and may lead to diagnostic uncertainty. In addition, the potential clinical 
utility of gene-panel testing is likely to be reduced by variability in disease expression and 
penetrance. In some clinical settings, gene panel testing is used in combination with other 
platforms including aCGH. For example, DSDs may arise from either single gene defects 
(>50 genes implicated) or from larger chromosomal abnormalities and combining genetic 
testing approaches can establish a genetic diagnosis in 40-60% of cases.47,57    
 
Whole Exome Sequencing (WES)/ Whole-Genome Sequencing (WGS) 
In contrast to disease-targeted gene panels, where prior knowledge of the likely causative 
gene is required, WES or WGS are suited to the investigation of individuals or kindreds 
suspected of genetic disease of unknown aetiology (i.e. ‘gene-discovery’ approach). In this 
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setting, both WES and WGS have been transformative in establishing the genetic aetiology 
of many monogenic endocrine disorders,1 and in contrast to earlier gene-discovery studies, 
have often facilitated successful gene discovery with small numbers of patients (i.e. without 
the need for extensive pedigrees).1,38,58-60 
 
WES limits analysis to the exome (i.e. the ~1-2% of the genome that comprises exons), 
which harbours the vast majority of variants responsible for Mendelian disease. In addition, 
WES sequences intron-exon boundaries and can therefore detects DNA variants 
affecting splice junctions.   In WES, prior to sequencing, the DNA sample undergoes a 
‘capture’ step in which oligonucleotide ‘baits’ (typically 60-100 nucleotides in length) are 
used to isolate the exonic regions (and intron-exon boundaries), whilst allowing the 
remainder of the genomic DNA to be discarded.  Thus, the accuracy of this approach is 
dependent on the reliability and efficiency of the capture step, which may be incomplete (i.e. 
leading to missing data). Following sequencing, bioinformatic tools are used to align the 
sequence reads to a reference genome, thereby allowing variant annotation. For clinical 
utility, the potential limitations of the approach need to be defined including the extent of any 
missing data (Figure 3). Clinical exome panels represent a modification of WES in which 
analysis is limited to genes with known disease associations (e.g. 4000-7000 genes). WGS 
represents the most comprehensive sequencing platform, providing unbiased coverage all 
coding and non-coding genomic regions with the potential to identify most types of genetic 
abnormality. The increased content results in the acquisition of very large data files and 
downstream bioinformatic analysis and interpretation is complex due to the huge numbers of 
variants identified.  
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Currently, the use of WES and WGS to evaluate patients or kindreds with endocrine disease 
is largely limited to the discovery setting although has been employed on clinical grounds as 
part of national sequencing efforts (e.g. Genomics England 100,000 Genome Project). More 
broadly, WES/WGS have particular clinical utility in the evaluation of patients with severe 
undiagnosed phenotypes in which a genetic aetiology in suspected.2,38,61 For example, both 
WES and WGS have resulted in high diagnostic yields in neonatal and paediatric 
populations with suspected monogenic disease.2,62,63 In this setting the availability of 
parental DNA samples may improve diagnostic yield, allowing the recognition of de novo 
genetic variants, and/or clarifying modes of inheritance.38 More recent studies confirm the 
clinical utility of WES/WGS in evaluating children and adults with complex undiagnosed 
disorders (including those with endocrine manifestations), enabling a genetic diagnosis to be 
established in ~35-40% of patients.39,64  
 
Challenges of Variant Interpretation  
The diagnosis of monogenic endocrine disorders relies on the accurate molecular and 
clinical interpretation of DNA sequence variants. However, recent large-scale sequencing 
projects (e.g. 1000 Genome Project,65,66 Exome Sequencing Project,67 ExAC,68 GnomAD, 
DiscoverEHR69) have revealed unexpectedly high rates of rare variation occurring in the 
background population, which hampers such interpretation.23 For example, each individual 
harbours ~3 million SNVs within their genome, and of these 1000-5000 will occur in the 
coding-region of known disease genes.5 In addition, most individuals harbour rare CNVs 
whose relevance to a given phenotype may be difficult to ascertain.70 Whilst variant filtering 
and bioinformatic tools enable the majority of genetic variants to be discounted from analysis 
on the grounds that they are unlikely to be disease-causing (e.g. based on population 
frequency and in silico predictions), NGS testing platforms will frequently identify a subset of 
potentially relevant variants that require more detailed evaluation. 
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Currently, the majority of Molecular Genetic Laboratories adopt the American College of 
Medical Genetics and Genomics (ACMG) guidelines to assess variant pathogenicity.18,71 
These guidelines are intended for the evaluation of penetrant monogenic disorders with well-
established disease-gene associations, and employ a multi-tiered approach, which 
considers a number of variant- and gene-specific factors (Table 2).18,71 The individual pieces 
of evidence are then considered in combination, and using pre-determined criteria, enable 
the classification of variant into one of five groups;  ‘benign’, ‘likely benign’, ‘uncertain 
significance’, ‘likely pathogenic’ or ‘pathogenic’ (although these categories are based on 
estimated probabilities and are not absolute)3. Although the ACMG guidelines provide a 
standardised approach to variant interpretation, there is considerable scope for variability 
and/or ambiguity in how specific criteria are applied, such that individual users may report 
different interpretations of the same variant.71 In addition, the appropriate application of 
individual criteria may be dependent on the availability of accurate information regarding 
disease prevalence and penetrance, the degree of genetic heterogeneity, knowledge of 
protein structure/function, and/or prior reports of variant classifications (e.g. from the 
literature or disease-specific variant databases), and in many instances these data may be 
absent or unreliable.71,73   
 
If a variant fails to meet the criteria for either a pathogenic/likely pathogenic or benign/likely 
benign categorization, it is stated to be of ‘uncertain significance’ (i.e. VUS). Variants in this 
category arise when there are either conflicting levels of evidence or incomplete/inadequate 
information, and may be associated with a continuum of risk spanning a range of 
probabilities. The challenge associated with the VUS category is highlighted by the 
observation that ~40% of all variants in the ClinVar database are reported to have this 
designation.74,75 Thus, the clinician needs to be aware of the potential for such ambiguous 
test results, and to appreciate that not all VUSs confer equal ‘risk’. In addition, it is important 
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to consider how VUS variants are communicated to the patient and whether individuals 
harbouring such variants require clinical follow up.  
 
Given the current limitations of variant interpretation, a number of initiatives have been 
established to enhance the reliability and/or application of existing ACMG guidelines. For 
example, the ClinGen consortium (www.clinicalgenome.org) has established processes to 
standardise the implementation of variant interpretation criteria for specific monogenic 
disease genes.76 Variant repositories such as ClinVar, which have previously been reported 
to have high rates of conflicting interpretations and an inflated number of pathogenic 
variants,72 allow continual variant re-evaluation by applying a rating system to the evidence 
supporting each submission.75 At the same time, high-throughput functional assays are 
being developed that allow the evaluation of large numbers of variants. For example, in 
vitro studies using saturation gene-editing, in which virtually all possible coding-
region SNVs are systematically engineered into the relevant gene to assess their 
functional impact, were recently employed to characterise ~4000 possible BRCA1 
SNVs, offering the potential for immediate downstream clinical utility.77 There has also been 
a continual evolution of computational tools used for in silico variant prediction. For 
example, the rare exome variant ensemble learner (REVEL) tool combines 13 
individual prediction algorithms into a single score, resulting in improved 
reliability.78,79 Similarly, statistical modelling, employing large population datasets, coupled 
with disease-specific information (e.g. penetrance, genetic heterogeneity, mode of 
inheritance) enable more stringent allele frequency cut-offs to be used in variant filtering, 
whilst Bayesian modelling has also been used in the application of components of the 
ACMG recommendations to enable a more quantitative framework for analysis.71,80-83 
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Although the clinician does not require a detailed knowledge of the methods employed for 
variant classification, it is important to recognise the limitations of such analysis and in 
particular, that an assertion of variant pathogenicity arising from molecular classification 
does not equate to a clinical diagnosis for the patient3. Instead, the genetic test result should 
be integrated into the overall clinical assessment (i.e. as a probabilistic biomarker), which 
accounts for the patient’s phenotype together with all other relevant information (e.g. family 
history), to allow a clinical-molecular diagnosis.3,71,74,84 Such ‘case-level’ interpretation may 
be hampered by incomplete disease penetrance, variable disease expressivity and 
incomplete phenotypic information and where diagnostic uncertainty exists, communication 
between the clinician and molecular genetics team (as well as the patient) is essential.85 
Furthermore, the interpretation of some variants may change as new information becomes 
available (e.g. large-scale population datasets, high-throughput functional assays, new 
disease-gene associations).  Thus, for variants where initial evaluation is uncertain, periodic 
re-evaluation should be considered. Likewise, as new disease-gene associations emerge, 
repeat genetic testing may be appropriate for those in whom prior testing has not yielded a 
diagnosis.  
 
Incidental Findings 
A further problem arising from the application of WES and WGS approaches in the clinical 
setting is the possibility of identifying pathogenic variants associated with disorders other 
than those for which the test was originally performed.86,87 Several studies have estimated 
that 1-4% of the population harbour a pathogenic variant in ‘actionable’ disease genes as 
defined by ACMG,5,69,87 although the disease risks associated with many such variants may 
have been inflated (e.g. due to inaccurate estimates of penetrance or pathogenicity due to 
ascertainment and reporting biases). There is controversy as to whether all clinical 
WES/WGS data should be analysed for such incidental findings and whether these variants 
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should always be reported back to the patient.85-89 Attempts to quantify the potential value of 
reporting actionable incidental findings have been made, taking into account disease 
‘severity’ and penetrance, as well as the potential efficacy and burden of clinical 
interventions resulting from a positive test, although there is currently a paucity of evidence 
to support a particular approach.85,90 For the endocrine field, the identification of 
asymptomatic individuals with pathogenic/likely pathogenic incidental findings in endocrine 
tumour genes (i.e. SDHB, SDHC, SDHD, SDHAF2, MEN1, RET, and VHL in current ACMG 
gene list) will likely result in increased demand for tumour surveillance programs.23 
Guidelines are required for the appropriate management of such individuals and until then 
patients will be subject to variable practice.  
 
SPECIAL SITUATIONS FOR TESTING 
 
Pre-implantation and Pre-natal genetic testing 
 
Pre-conception genetic counselling together with associated genetic testing provides an 
important component of clinical care for prospective (or existing) parents at risk of 
transmitting genetic disorders to their offspring. This includes individuals with a pre-existing 
genetic diagnosis, carriers of disease-associated mutations, or parents in whom previous 
pregnancies or offspring have been affected by genetic disease.  Increasingly, pre-
implantation genetic diagnosis (PGD) may be offered in situations where parents are at risk 
of transmitting severe monogenic disorders40,91 and has been successfully employed in the 
context of MEN1,92 MEN2,93 and CAH.94 PGD is only possible in the context of in vitro 
fertilization (IVF), and involves the sequencing of DNA isolated from a small number of early 
blastocyst cells.40,91 Knowledge of the genetic status of each pair of parental alleles is 
required to ensure that both maternal and paternal alleles are adequately sequenced in the 
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blastocyst cells. Having established the genetic status of a set of blastocysts, a ‘low risk’ 
embryo (e.g. without the mutation) is transferred to the mother. For autosomal recessive 
disorders, if no mutation-free blastocysts are identified, transfer of an embryo carrying one 
defective allele may be considered, in the knowledge that the offspring will be a mutation 
carrier. Due to the potential for false negative results in PGD (e.g. due to allele ‘drop-out’ 
in which only one of the two target alleles is successfully amplified during 
sequencing), pre-natal genetic testing is recommended once pregnancy is established.40,91 
In principle, similar methods can be used for genetic disorders associated with structural 
chromosomal abnormalities,91 whilst PGD can also be employed in specific settings to 
reduce the risk of transmitting disorders associated with mitochondrial DNA 
mutations (i.e. by identifying embryos with a low mutation load).95 
 
In contrast to PGD, pre-natal genetic testing evaluates the genetic status of the foetus once 
pregnancy is established and can be used to detect aneuploidy, chromosomal abnormalities 
or single gene defects. Indications for testing include scenarios in which there is an 
increased risk of transmission of a hereditary disease, or where antenatal screening has 
identified features suggestive of a genetic diagnosis.  Typically, pre-natal genetic testing 
involves invasive approaches to acquire foetal DNA for evaluation (i.e. chorionic villous 
sampling, amniocentesis), which carry a 0.5-1% miscarriage rate. Non-invasive prenatal 
genetic diagnosis (NIPD) and/or testing (NIPT) avoids such risks and relies on the analysis 
of cell-free circulating foetal DNA, which is released into the maternal circulation from the 
placenta, and is detectable from ~5-6 weeks gestation. NIPD is most widely used for the 
detection of aneuploidy and foetal sex determination, which may be important for X-linked 
disorders or where the severity of the clinical phenotype is sex-dependent (e.g. congenital 
adrenal hyperplasia (CAH)).46 For monogenic disorders, paternally-inherited or de novo 
mutations can be identified by NIPT, whilst the identification of maternally-inherited 
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mutations is more challenging and requires highly sensitive methods to differentiate foetal 
from maternal DNA. 
 
Somatic Genetic Testing for Endocrine Cancers 
Evaluating tumour samples for recurrent somatic (i.e. non-germline) ‘driver’ mutations may 
have diagnostic, prognostic and therapeutic value and has become part of standard clinical 
care for several cancer (e.g. EGFR and ALK mutation testing in non-small cell lung cancer; 
BRAF Val600 mutations in malignant melanoma)96. Currently, such approaches have 
limited clinical utility in the endocrine field, although are gaining traction in specific 
settings. For example, BRAF inhibitors (e.g. vemurafenib, dabrafenib) have shown 
promise in the treatment of papillary craniopharyngiomas harbouring the somatic 
BRAF (Val600Glu) mutation,97,98 whilst somatic mutation testing of MTC may have 
future clinical value in guiding therapy with selective RET kinase inhibitors.99 In the 
research setting, the genetic profiling of endocrine tumours with WES/WGS has been 
transformative in defining the mutational landscape of such tumours frequently leading to the 
identification of many new ‘driver’ genes (e.g. USP8 mutations in corticotroph 
adenomas;100,101 ATRX/DAXX mutations in pancreatic neuroendocrine tumours;102,103 KCNJ5 
mutations in aldosterone-producing adenomas).104 A current challenge is translating these 
advances into clinical benefit and in this regard many potential applications are emerging, 
including several related to thyroid cancer. For example, the utility of a NGS gene panel to 
improve the diagnostic accuracy associated with indeterminate cytology thyroid nodules has 
been assessed using the ThyroSeq v2.1 panel,105 which combines the detection of somatic 
mutations in thyroid cancer-associated genes (e.g. BRAF, HRAS, NRAS, KRAS), with gene 
expression data, and was reported to have a sensitivity and specificity for diagnosing thyroid 
cancer of 91% and 92%, respectively.106 Establishing how tumour genomics and molecular 
profiling can be exploited to identify novel therapeutic targets and/or ensuring the optimal 
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use existing targeted therapies is a major priority, particularly for cancers for which current 
treatments are limited (e.g. adrenocortical carcinoma, metastatic PPGL, pancreatic 
NETs).107 In this regard novel precision oncology approaches combining tumour 
transcriptome profiles with complex bioinformatic algorithms have been reported to hold 
promise.108 A final potential application of clinical genetic testing related to cancer is the 
emerging use of circulating cell-free DNA (cfDNA) for diagnosis, disease stratification and/or 
disease monitoring (i.e. the ‘liquid-biopsy’).109 These methods exploit the release of tumour 
DNA into the circulation (i.e. circulating-tumour DNA (ctDNA)), which may be amplified or 
captured prior to NGS sequencing, allowing the detection of DNA sequence alterations 
arising from the cancer. Currently, these methods are not in clinical practice for endocrine 
cancers, but preliminary studies indicate potential utility in specific settings including the 
monitoring of advanced thyroid cancer.110 
FUTURE DIRECTIONS & CONCLUDING REMARKS 
The recent advances in DNA sequencing offer unparalleled opportunities for genetic testing 
in mainstream clinical practice with costs of high-content tests (i.e. gene panel, WES/WGS) 
now falling to those of other routinely employed diagnostic tests (e.g. cross-sectional 
imaging). However, the advances in sequencing technology have not been paralleled by 
similar progress in understanding the biological and/or clinical relevance of the huge 
diversity of genomic variation evident at both the individual and population level.54 As a 
consequence, the current interpretation of high-content tests, including assessments of 
variant pathogenicity, remains extremely challenging. On-going large-scale sequencing 
projects, which simultaneously collect detailed clinical information (e.g. utilising electronic 
health records) aim to address some of these deficiencies (e.g. NIH-funded eMERGE and 
IGNITE networks),4 as do several laboratory- and bioinformatic-based studies. Despite the 
improved knowledge that such studies bring, there also remains a need to understand how 
genetic variants interact with other genes, the environment and/or additional modifying 
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factors (e.g. epigenetic modifications) to influence disease expressivity and/or disease 
penetrance.74 
 
Looking forward, it is likely that genetic testing will move into other settings. For example, 
there is a growing debate on the use of germline genetic testing for primary screening at a 
population-level to identify individuals at risk of serious disease, including monogenic cancer 
syndromes.111-115 Testing in this setting could include the detection of hereditary endocrine 
tumour syndromes (e.g. MEN1, MEN2, VHL, PPGL due to SDHX mutations) and a 
predictable outcome of this approach would be the identification of large numbers of 
asymptomatic individuals harbouring pathogenic/likely pathogenic or VUS variants, which in 
turn will likely place an increased burden on endocrine services due to an expansion in 
tumour surveillance programs. In this setting, variant interpretation is more challenging, 
given the lack of clinical context to the molecular classification.71,84 Prior to the adoption of 
any such programs, improved probabilistic models are required to estimate more accurately 
the likelihood that an individual harbouring a given variant will develop disease.71 However, 
the recent FDA first marketing authorization for direct-to-consumer genetic testing for 
specific BRCA mutations indicates the likely direction of travel for population-based 
testing.116 Other emerging areas for genetic testing include pharmacogenomic assays to 
identify individuals with enhanced, reduced or adverse responses to specific therapies (e.g. 
association of aminoglycoside ototoxicity with a mitochondrial DNA mutation).117 
Furthermore, recent studies indicate considerable genetic variation in drug-targeting sites of 
many G-protein coupled receptors (GPCRs), which may provide an area of furtive research 
for the endocrine field.118 Likewise, another recent study demonstrated asthma patients 
carrying specific genetic variants in the PDGFR gene were at increased risk of steroid-
induced adrenal suppression.119 Thus, it is possible that genetic testing may not only be 
used to guide therapy but also to predict those at increased risk of adverse endocrine 
outcomes. 
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Finally, the increased use of genetic testing in the clinical settings requires enhanced 
communication between the physician and clinical geneticist, as well as transparency and 
openness with the patient (and wider family). However, many questions remain unresolved, 
including; how best to obtain genuinely informed consent; how to effectively communicate 
ambiguous or uncertain test results; should incidental findings always be evaluated and 
reported; how can genetic data be shared effectively whilst preserving patient privacy? 
These issues apply to the whole medical community and are not unique to endocrinology. 
Ultimately, despite the rapid progressing made, it will likely take many years before the 
potential health benefits associated with increased genetic testing can be fully assessed. 
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Figure Legends 
 
Figure 1. Penetrance estimates for monogenic endocrine tumour disorders.  
For several hereditary endocrine tumour syndromes, establishing accurate estimates of 
disease penetrance may be challenging and in many instances prior estimates are likely to 
have been overstated due to ascertainment and reporting biases (e.g. resulting from the 
inclusion of index cases in calculations and/or the inadequate genetic investigation of control 
populations). A number of recent studies have demonstrated unexpectedly high frequencies 
of disease-associated variants in the background population, facilitating revised estimates of 
disease penetrance for several endocrine tumour genes.12,23,120,121 In addition, although 
estimates of disease penetrance are frequently reported at the gene level, different 
pathogenic variants in the same gene may be associated with marked differences in 
penetrance. For example, although the majority of MEN2A-associated RET mutations are 
reported to have a high disease penetrance (e.g. 70-100% by the age of 70 years), recent 
population-level studies predict that the Val804Met variant has a much lower penetrance of 
1-8% (dashed box).24 In addition, distinguishing low penetrance disease alleles from benign 
variants is challenging and typically requires large disease and control cohorts to establish 
genuine associations. For example, a recent study demonstrated that several AIP missense 
variants previously reported to be pathogenic in individuals with pituitary adenomas were no 
more frequent in this setting than in control populations23. Germline variants with reduced 
penetrance may be indicated by an absence of relevant family history (i.e. occurring in 
apparently sporadic disease settings).103,122 For the figure above, estimates of disease 
penetrance were established from: Genetic Home Reference (https://ghr.nlm.nih.gov/); 
Online Mendelian Inheritance in Man (OMIM; https://www.omim.org/); and literature-based 
estimates. Penetrance estimates for monogenic tumour syndromes are often expressed as 
the likelihood of developing disease by a given age and as a consequence estimates may 
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not be comparable. As such the penetrance estimates above are intended to be illustrative. 
References relevant to specific genes include: AIP;19,42 CDC73;123,124 MEN1;26,125 SDH 
complex genes;11,12,120,121 PRKAR1A;28 RET;23,24,126 VHL.127 Penetrance estimates for MEN4 
due to CDKN1B mutations are not available due to low numbers of reported cases.128 
Abbreviations: FIPA, Familial isolated pituitary adenoma syndrome; HPT-JT, 
Hyperparathyroidism-Jaw Tumour Syndrome; PC, Parathyroid carcinoma; PPGL, 
phaeochromocytoma/paraganglioma. 
 
Figure 2. Illustrative workflow for clinical genetic testing 
The genetic testing workflow can be divided into three phases:  pre-test, testing and 
molecular interpretation, and post-test. The pre-test phase includes the appropriate 
identification of individuals in whom genetic testing may be appropriate. In the diagnostic 
setting, this often requires a high index of suspicion and is dependent on a thorough 
evaluation of the patient and establishing any relevant family history. For those in whom a 
genetic diagnosis is suspected the decision to undertake testing should consider the 
potential utility of establishing a diagnosis, as well as the most appropriate testing strategy. 
Informed consent should address any patient concerns, and should be tailored to the testing 
strategy planned. Consent may also seek to gain permission for storage and future testing of 
DNA samples, contact with relevant family members if considered clinically indicated, and 
establish how ambiguous test results and/or incidental finding are dealt with. Genetic testing 
undertaken on a research basis requires different ethical permissions and the testing 
platforms may not have the same validity required for clinical testing. All testing and 
molecular classification should be undertaken in accredited laboratories. The interpretation 
of genetic variants should follow standardised processes (e.g. adhering to ACMG guidelines) 
that enable classification of variants into one of 5 classes (i.e. pathogenic, likely pathogenic, 
benign, likely benign and uncertain significance).  However, the clinician needs to be aware 
of the limitations of such systems and to recognize that the molecular classification of 
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variants does not equate to a clinical diagnosis. Instead, during the post-test phase, the 
genetic test result should be incorporated into the overall clinical assessment of the patient. 
Where there is doubt, discussion with the clinical and molecular genetics team should aim to 
determine whether any additional support for a particular diagnosis can be established. If the 
clinical phenotype strongly points to a particular genetic diagnosis, but initial testing is 
negative, it may be appropriate to consider a different testing platform. When molecular 
classification identifies a variant of uncertain significance, decisions regarding how such 
results are communicated to the patient, and whether clinical follow-up is required often 
require multidisciplinary working. It is also possible that variant classification may change 
over time as additional information becomes available.  
 
Figure 3: DNA sequencing methods and their utility in the diagnosis of monogenic 
endocrine disorders 
The most appropriate DNA sequencing method to diagnose a monogenic endocrine disorder 
will be determined by the clinical setting, as well as the local availability of testing platforms. 
Although NGS-based sequencing methods have gained increased traction in the clinical 
setting, Sanger sequencing of one or more individual genes (either targeted to specific 
exons or covering the whole coding-region) retains an important role in the diagnosis of 
monogenic disorders with low genetic heterogeneity (e.g. RET mutations in MEN2A or 
MEN2B), and is also used for predictive genetic testing (e.g. for first-degree relatives of 
patients with known disease-associated mutations). In addition, Sanger sequencing is used 
to confirm the presence of likely pathogenic variants found by high-content NGS methods. 
Sanger sequencing will not reliably detect partial or whole gene deletions, which may 
account for a proportion of individuals with specific monogenic disorders (e.g. MEN1, Carney 
complex), and when this is suspected, alternate methods of detection are required (e.g. 
MLPA/CGH array). Disease-targeted gene panels are increasingly employed to investigate 
disorders with high genetic heterogeneity (e.g. PPGL, disorders of calcium homeostasis), 
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enabling the cost-effective sequencing of multiple genes simultaneously. The majority of 
panels employ NGS methods, following either bait-based capture or PCR-based 
amplification of the targeted exons. However, it is possible that some genomic regions will 
be ‘missed’ (e.g. due to incomplete ‘capture’ of target regions). In mainstream clinical 
practice, WES and WGS are rarely used to diagnose monogenic endocrine disorders, 
although each has been pivotal for endocrine disease-gene discovery in the research 
setting. These approaches are reported to have clinical utility in both paediatric and adult 
settings for the investigation of patients with severe undiagnosed phenotypes,39 and retain a 
critical role in the research investigation of individuals and/or kindreds with genetic disorders 
of unknown aetiology. However, an important consideration prior to undertaking WES/WGS 
is the challenge of variant interpretation. For example, it is estimated that every individual 
will harbour ~1000-5000 coding-region variants in disease-associated genes, of which ~1% 
are likely to be categorized as of potential functional significance (i.e. VUS or likely 
pathogenic/pathogenic status).5 In the absence of additional information (e.g. availability of 
parental samples to identify de novo mutations, segregation data in a kindred with multiple 
affected individuals) interpreting such variants remains problematic and may not inform the 
clinical picture. Furthermore, ~3-5% of the population are predicted to harbour incidental 
findings (i.e. potential  
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Table 1. Examples of Existing and Emerging Indications for Genetic Testing in Adult and Paediatric Endocrinology 
Disorder/Phenotype Gene (Chromosome location) or 
Chromosomal abnormality 
Variant 
Type 
Inherit. 
Pattern 
Genetic Test(s) Clinic. 
Set
a
 
Notes 
Multi-System Monogenic Endocrine Tumour Syndromes      
Multiple Endocrine Neoplasia Type 1 
(MEN1) 
MEN1 (11q13.1) SNV/Indel 
Gene del 
AD Single gene/Panel 
(MLPA/aCGH
b
) 
Ad/P MEN1 mutations observed in ~70-90% of index cases with 
≥2 clinical manifestations (parathyroid, pituitary, pancreatic 
endocrine tumours) and a positive family history  
Multiple Endocrine Neoplasia Type 
2A/2B (MEN2A/MEN2B) 
RET (10q11.21) SNV AD      Single gene/Panel Ad/P Strong genotype-phenotype correlation is observed such 
that sequencing may be limited to specific RET exons 
Multiple Endocrine Neoplasia Type 4 
(MEN4) 
CDKN1B (12p13.1) SNV/Indel 
Gene del? 
AD Single gene/Panel 
(MLPA/aCGH
b
) 
Ad/P Only a few cases of MEN4 are reported to date such that a 
full clinical description is not currently available 
Hyperparathyroidism Jaw-Tumour 
Syndrome (HPT-JT) 
CDC73 (1q31.2) SNV/Indel 
Gene del 
AD Single gene/Panel 
(MLPA/aCGH
b
) 
Ad/P In addition to parathyroid tumours patients may manifest 
ossifying fibromas of the jaw, renal and uterine tumours  
von Hippel Lindau Syndrome (VHL) VHL (3p25.3) SNV/Indel 
Gene del 
AD Single gene/Panel 
(MLPA/aCGH
b
) 
Ad/P Genotype-phenotype correlation observed with increased 
risk of PPGL in association with missense VHL mutations  
Neurofibromatosis Type 1 (NF1) NF1 (17q11.2) SNV/Indel 
Gene del 
AD Single gene/Panel 
(MLPA/aCGH
b
) 
(Ad)/P Endocrine manifestations may include PPGL, pancreatic 
NETs, GH hypersecretion, precious puberty and carcinoids 
McCune-Albright Syndrome (MAS) GNAS (20q13.32) SNV S.Mos
c
 Single gene/Panel P Somatic missense GNAS mutations affecting Arg201 and 
Gln227 residues are most commonly reported. 
Carney Complex PRKAR1A (17q24.2) SNV/Indel 
Gene del 
AD Single gene/Panel 
(MLPA/aCGH
b
) 
P A characteristic endocrine feature is Cushing syndrome due 
to primary pigmented nodular adrenocortical disease  
Hypothalamic /Pituitary Disorders      
Familial Isolated Pituitary Adenoma 
(FIPA)  
AIP (11q13.2),  SNV/Indel 
Gene del/ 
AD/ 
 
Single gene/Panel 
(MLPA
b
) 
Ad/P Founder AIP mutations may be prevalent in specific 
populations (e.g. Arg304Ter mutation in regions of Ireland).  
X-linked Gigantism (XLAG) GPR101 (Xq26.3) Gene dup XLD 
De novo 
S.Mos
c
 
aCGH/ 
ddPCR 
P Female cases typically harbour de novo germline GPR101 
duplications. Sporadic male cases occur due to somatic 
mosaicism. Mother-to-son transmission also observed.  
Combined Pituitary Hormone 
Deficiency (CPHD) 
PROP1 (5q35.3), HESX1 (3p14.3), LHX3 
(9q34.3), LHX4 (1q25.2), OTX2 (14q22.3), 
POUF1F1 (3p11.2), SOX2 (3q26.33) + more 
SNV/Indel AD/AR/ 
XLD 
Gene Panel +/-
CNV detection 
P 
 
Mutations in specific genes may result in additional features 
including intellectual disability, septo-optic dysplasia (e.g. 
HESX1, OTX2 and SOX2 mutations) 
Hypogonadotrophic hypogonadism 
with or without anosmia 
ANOS1 (Xp22.31), FGFR1 (8p11.23), 
PROKR2 (20p12.3), CHD7 (8q12.2), FGF8 
(10q24.32), PROK2 (3p13) + more 
SNV/Indel AD/AR 
/XLR 
Gene Panel Ad/P >20 genes implicated. Some patients may have mutations in 
more than one gene and inheritance patterns are dependent 
on the gene(s) implicated (e.g. monogenic and oligogenic) 
Adrenal Disorders       
Autoimmune polyglandular 
syndrome type 1 
AIRE (21q22.3) SNV/Indel AR (AD) Single gene/Panel Ad/P Majority of kindreds demonstrate AR inheritance, although 
dominant-negative activity observed for specific mutations 
Congenital Adrenal Hyperplasia CYP21A2 (6p21.33), CYP11B1 (8q24.3), 
CYP17A1 (10q24.32)  
SNV/Indel AR Single gene/Panel P Severity of phenotype is governed by the gene involved and 
the degree of the respective enzyme deficiency  
X-linked adrenoleucodystrophy  (X-
ALD) 
ABCD1 (Xq28) SNV/Indel XLD Single gene/CNV 
analysis 
P/Ad Cerebral forms typically present in childhood whereas the 
adrenomyeloneuropathy types may manifest in adulthood.  
Familial Glucocorticoid Deficiency MC2R (18p11.21), NNT (5p12), MRAP 
(21q22.11), STAR (8p1123), TXNRD2 
(22q11.21) + others 
SNV/Indel AR Single gene/Panel P Presents in neonatal period/early childhood with features of 
glucocorticoid deficiency (e.g. hypoglycaemia). STAR 
mutations associated with XY sex reversal 
Hereditary Phaeochromocytoma / 
Paraganglioma (PPGL) 
SDHB (1p36.13), SDHC (1q23.3), SDHD 
(11q23.1), SDHAF2 (11q12.2), MAX 
(14q23.3), RET (10q11.21), VHL (3p25.3), 
NF1 (17q11.2), TMEM127 (2q11.2) + others 
SNV/Indel 
Gene del 
AD Single gene/Panel 
(+CNV analysis) 
P/Ad Specific SDH genes may be associated with non-endocrine 
cancers (e.g. GISTs, renal cell carcinoma). Prioritised 
analysis of genes may be governed by clinical phenotype  
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Adrenocortical Carcinoma (ACC) TP53 (17p13.1) + others (e.g. mismatch 
repair genes, MEN1, APC) 
SNV/Indel 
Gene del 
AD 
 
Single gene/Panel P/Ad The majority of children with ACC have germline TP53 
mutations associated with Li-Fraumeni Syndromes.   
Familial Hyperaldosteronism CYP11B1/2 (8q24.3), KCNJ5 (11q24.3), 
CACNA1D (3p21.1), CACNA1H (16p13.3)  
SNV/Gene 
Fusion 
AD Single gene/Panel 
Long-range PCR 
P/Ad Familial hyperaldosteronism type 1 results from a chimeric 
CYP11B1/2 enzyme. 
Calcium/Phosphate Homeostasis       
Familial Isolated 
Hypoparathyroidism (FIH) 
GCM2 (6p24.2), PTH (11p15.3) SNV/Indel 
Gene del 
AD/AR 
 
Single gene/Panel P/Ad Both autosomal dominant and recessive forms reported in 
association with PTH and GCM2 mutations.  
Autosomal Dominant 
Hypocalcaemia (ADH)  
CASR (3q13.33-q21.1), GNA11 (19p13.3) SNV AD 
 
Single gene/Panel P/Ad Majority of case due to activating CASR mutations, with a 
small minority due to GNA11 mutations.  
22q11.2 deletion syndrome 
(DiGeorge) 
3Mb deletion on chromosome 22 containing 
30-40 genes including TBX1 
- De novo 
/AD 
CGH/FISH/ 
MLPA 
Ad/P Deletion of TBX1 gene thought to account for majority of 
clinical features. Majority of cases due to de novo mutation 
Pseudohypoparathyroidism type 1a / 
Pseudopseudohypoparathyroidism 
(PHP1a/PPHP) 
GNAS (20q13.32) SNV/Indel/
Gene del 
 
AD Single gene Ad/P Maternally and paternally inherited GNAS mutations are 
associated with PHP1a and PPHP, respectively (i.e. parent 
of origin effects) 
Familial Isolated 
Hyperparathyroidism (FIHP) 
MEN1 (11q13.1), CASR (3q13.33-q21.1), 
CDC73 (1q31.2), GCM2 (6p24.2) 
SNV/Indel/ 
Gene del 
AD Single gene/Panel Ad/P Before diagnosing FIHP it is important to exclude additional 
clinical manifestations (e.g. associated with MEN1, HPT-JT)  
Familial Hypocalciuric 
Hypercalcaemia (FHH)  
CASR (3q13.33-q21.1), GNA11 (19p13.3) 
AP2S1 (19q13.32) 
SNV/Indel/ 
Gene del 
AD Single gene/Panel Ad/P Neonatal severe hyperparathyroidism (NSHPT) results from 
autosomal recessive inheritance of LOF CASR mutations 
Hereditary Hypophosphataemic 
Rickets 
PHEX (Xp22.11), CLCN5 (Xp11.23), FGF23 
(12p13.32) + others 
SNV/Indel/ 
Gene del 
XLD/ 
XLR/AD/
AR 
Single gene/Panel P XLD inheritance observed with PHEX mutations; XLR 
inheritance observed with CLCN5 mutations. AD and AR 
forms are observed in association with other genes 
Thyroid Disorders       
Congenital Hypothyroidism TSHR (14q31.1), PAX8 (2q14.1), DUOX2 
(15q21.1), SLC5A5 (19p13.11), TSHB 
(1p13.2), THRA (17q21.1) + others 
SNV/Indel AR/AD Single gene/Panel P THRA mutations are associated with Resistance to Thyroid 
Hormone-α with clinical features of severe hypothyroidism. 
THRA is included on many congenital hypothyroidism panels 
Thyroid Hormone Resistance (THR) THRB (3p24.2), THRA (17q21.1) SNV/Indel AD/(AR) Single gene/Panel P/Ad Majority of THR cases associated with AD inheritance  
Disorders of Glucose Homeostasis      
Neonatal and Infancy-Onset 
Diabetes 
ABCC8 (11p15.1), KCNJ11 (11p15.1), GCK 
(7p13), INS (11p15), PDX1 (13q.12)+ others 
SNV/Indel AD/AR/ 
de novo 
Single gene/Panel P Phenotype due to defects in pancreatic development or β-
cell function/survival. Defects at 6q24 account for majority of  
Autosomal Dominant Familial Mild 
Hyperglycaemia / Diabetes (MODY) 
HNF4A (20q13.12), GCK (7p13), HNF1A 
(12q24.31), HNF1B (17q12)+ others 
SNV/Indel AD Single gene/Panel P/Ad Mutations in GCK, HNF1A and HNF4A account for majority 
of cases although ≥14 genes implicated in MODY phenotype 
Congenital Hyperinsulinism ABCC8 (11p15.1), KCNJ11 (11p15.1), GCK 
(7p13) + others  
SNV/Indel AD/AR Single gene/Panel P Mutations in at least 9 genes associated with phenotype. 
Diffuse forms usually have AR inheritance 
Disorders of Sex Development/ Sex Chromosome abnormalities      
46,XY Disorder of Sex Development 
(DSD)/Ambiguous genitalia 
SRY (Yp11.2), AR (Xq12), NR5A1 (9q33.3), 
HSD17B3 (9q22.32), MAMLD1 (Xq28), 
SRD5A2 (2p23.1), MAP3K1 (5q11.2), 
NROB1 (Xp21.2), DHH (12q13.12) + others 
SNVs/ 
Indels/ 
Gene del/ 
CNVs 
NI 
(AD/AR) 
aCGH 
/FISH/Panel 
P >30 genes implicated in DSD.  De novo genetic variants are 
common. Occasional Y-linked inheritance for SRY gene.  
Some genes may manifest AD or AR inheritance.  
Turner syndrome Aneuploidy 45 X  (loss or partial deletion/ 
rearrangement of one X chromosome) 
- NI Karyotype/aCGH Ad/P May occur in mosaic forms with potentially milder phenotype 
Klinefelter syndrome Aneuploidy 47 XXY  (typically having one 
additional copy of X chromosome)  
- NI Karyotype/aCGH Ad/P May occur in mosaic forms with potentially milder phenotype 
Prader-Willi syndrome (PWS) Paternal deletion, maternal uniparental 
disomy or occasional translocations 
involving part of chromosome 15 
- NI 
 
d
Methylation 
specific MLPA 
/aCGH/ FISH 
P/Ad The genetic changes associated with PWS usually occur de 
novo but very rarely can be inherited 
Miscellaneous       
Multi-system complex phenotype Unknown SNV/Indel/ variable aCGH,, P/Ad The inclusion of parental samples may help identify de novo 
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with endocrine manifestations CNV WES/WGS mutations (i.e. ‘trio’ testing) 
This table is not intended to be comprehensive but rather to highlight the diversity of conditions for which genetic testing may be considered. The information included in this table is largely derived from: Genetics Home 
Reference (www.ghr.nlm.nih.gov); OMIM (www.omim.org); and Genetic Testing Registry (www.ncbi.nlm.nih.gov). 
a
 Describes whether genetic testing for the respective condition is typically undertaken in Paediatric (P) and/or Adult (Ad) clinical settings.  
b
 Several monogenic disorders may result from partial or whole gene deletions, which may not be detected by single gene or gene panel testing. In this setting alternate methods may be required including MLPA, aCGH, or 
FISH. Some NGS sequencing platforms including those used in gene panel testing may also detect these large-scale deletions. 
c
 Several endocrine disorders may be associated with post-zygotic somatic mosaicism (S.Mos) (e.g. XLAG, McCune Albright syndrome). Although genetic testing of blood-derived DNA frequently identifies the genetic 
abnormality, in some settings alternate tissue samples are required for analysis (e.g. pituitary tissue in sporadic XLAG) 
d
 Methylation-specific MLPA is a modification of MLPA that can detect epigenetic alterations including those observed in imprinting disorders such as Prader-Willi syndrome.  
Abbreviations: P, paediatric; Ad, adult; MOS, mosaicism; aCGH, array comparative genomic hybridization; AD, autosomal dominant; AR, autosomal recessive; XLD, X-linked dominant; XLR, X-linked recessive; CNV, copy 
number variant; SNV, single nucleotide variant; PCR, polymerase chain reaction; NI, not inherited; Gene del, gene deletion; Gene dup, gene duplication; PPGL, phaeochromocytoma/paraganglioma; NET, neuroendocrine 
tumour; S.Mos, somatic mosaicism; ddPCR, droplet digital polymerase chain reaction. 
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Table 2. Factors employed for variant interpretation by ACMG guidelines 
Variant 
characteristic 
Evidence supporting pathogenic interpretation 
(strength of evidence) 
Evidence supporting benign 
interpretation (strength of evidence) 
Population data
a
 Increased prevalence of variant in affected 
individuals compared to controls (e.g. Odds Ratio 
>5) (STR) 
Absence of variant in control population (e.g. 
GnomAD, ExAC) (MOD) 
Minor Allele frequency >5% (SA) 
Variant frequency in controls too high for 
disorder (STR) 
Variant observed in healthy adult control and 
is inconsistent with known disease 
penetrance (i.e. fully penetrant) (STR) 
Segregation 
information
b
 
Co-segregation of variant with disease in multiple 
affected family members (SUP-STR) 
Non-segregation of variant with disease 
(STR) 
Predictive data and 
Computational tools 
Predicted LOF/null variant in gene where LOF is a 
known mechanism of disease (V.STR) 
Same predicted amino acid change as known 
pathogenic variant (STR) 
Variant predicted to result in novel missense amino 
acid change at residue known to be affected by a 
different pathogenic missense mutation (MOD) 
Multiple lines of computational evidence support a 
deleterious effect on gene function (SUP) 
Variant predicted to result in protein length change 
as a result of an in-frame insertion/ deletion or stop-
loss variant (MOD) 
Missense mutations in which only truncating 
mutations cause disease (SUP) 
Synonymous/silent variant with no predicted 
impact on splicing (SUP) 
In-frame insertion/deletion in repeat region 
without known function (SUP) 
Multiple lines of computational evidence 
suggest no impact on gene/gene product 
(SUP) 
Functional impact Well established functional studies show a 
deleterious effect (STR) 
Variant occurs in mutational hotspot/ functional 
domain without benign variation (MOD) 
Missense variant in gene in which missense 
variants are rare, and pathogenic missense variants 
occur frequently (SUP) 
Well established functional studies show no 
deleterious effect (STR) 
 
De novo data
c
 Confirmed de novo variant (i.e. maternity and 
paternity confirmed) in gene known to be associated 
with patient’s phenotype (STR) 
Assumed de novo variant (maternity and paternity 
not confirmed) in gene known to be associated with 
patient’s phenotype (MOD) 
NA 
Allelic data For autosomal recessive disorders the variant 
occurs in trans with known pathogenic variant 
(MOD) 
Variant occurs in trans with known 
pathogenic variant (for dominant disorders) 
or in cis with known pathogenic variant (for 
both dominant and recessive disorders) 
(SUP) 
Database data
d
 Reputable source reports variant as pathogenic but 
evidence is not available to perform independent 
evaluation (SUP) 
Reputable source reports variant as benign 
but evidence is not available to perform 
independent evaluation (SUP) 
Additional data
e
 Patient’s phenotype and family history highly 
specific for a disease with a single genetic aetiology 
(SUP) 
Variant occurs together with a second 
variant in a different gene for which disease 
association is more compelling (SUP) 
Footnotes: The above guidance is based on the ACMG guidelines reported in Richards et al Genet Med 2015. These 
guidelines are intended for use for monogenic disorders with relatively high penetrance and for variants in genes with 
established disease causality. Additional details regarding the criteria for variant classification system is found in these 
guidelines.
18
 
a 
It is Important that the control population data is matched to that of the patients under study (i.e. relevant geographical 
background)  
b
 The strength of evidence may vary according to the extent of the segregation data. Segregation data may be unreliable where 
penetrance is reduced, with late-onset disease or where clinical assessment of individuals within the kindred is incomplete. 
Occasionally, the variant under review may be in linkage disequilibrium with the ‘true’ pathogenic variant 
c
 De novo variants are observed in all individuals and cannot by themselves be taken as very strong (V.STR) or stand alone 
(SA) evidence of pathogenicity 
d
 The reliability of variant databases may be reduced (e.g. inaccurate estimates of variant pathogenicity). Therefore, caution is 
required when relying on such databases unless additional supporting evidence is provided with the submission.  
e 
A recent study has proposed locus-specific adjustments to the ACMG-AMP guidelines for missense variants in the MEN1 
gene which place additional weight on patient phenotype and family history (Romanet et al, Hum Mut 2019).
72
 
Abbreviations and additional terminology; SA, Stand Alone; STR, strong; V.STR, very strong), MOD, moderate; SUP, 
supporting; cis, occurring on the same chromosome; trans, occurring on the opposing allele)  
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